ArticleAnnals of gastroenterology
Blood eosinophilia in patients with inflammatory bowel disease losing response to biologics.
Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging data suggest that blood eosinophilia may be linked to inflammatory bowel disease (IBD) activity and biologic treatment failure. This study assessed the occurrence of eosinophilia in IBD patients experiencing biologic failure. Methods: This was a single-center retrospective study of IBD patients treated with infliximab (IFX) or vedolizumab (VDZ) between 2017 and 2023. Demographics, disease characteristics, disease activity, treatment modifications, together with data on blood eosinophilia and persistent blood eosinophilia, were recorded at 1-year follow up following treatment initiation with biologics. The outcomes were rate of biologic failure, hospitalizations, and surgery at 1 year. Uni- and multivariate analyses were performed to identify factors associated with these outcomes. Results: The study included 154 patients, 96 with Crohn's disease (CD) (62.3%) and 58 with ulcerative colitis (UC) (37.7%). The occurrence of blood eosinophilia was observed in 22% of patients over 1 year of followup. In univariate analysis, factors associated with biologic failure included previous biologic exposure (P<0.001), baseline immunosuppressants (P=0.009), baseline perinuclear antineutrophil cytoplasmic antibody (P=0.041), and blood eosinophilia (P=0.037). Blood eosinophilia was associated with a higher risk of VDZ failure (odds ratio [OR] 2.81, 95% confidence interval [CI] 1.01-8.10; P=0.047) and was more frequently observed in patients with CD than in UC (OR 2.97, 95%CI 1.05-8.91; P=0.040). Multivariate analysis confirmed the association of blood eosinophilia and biologic failure (OR 2.65, 95%CI 1.08-6.65; P=0.034). Conclusion: Blood eosinophilia was independently associated with biologic failure at 1 year in IBD patients and may represent a risk-stratifying biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.